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AbstrACt
The purpose of this paper is to help readers choose an 
appropriate observational study design for measuring 
an association between an exposure and disease 
incidence. We discuss cohort studies, sub- samples from 
cohorts (case- cohort and nested case- control designs), 
and population- based or hospital- based case- control 
studies. Appropriate study design is the foundation of a 
scientifically valid observational study. Mistakes in design 
are often irremediable. Key steps are understanding the 
scientific aims of the study and what is required to achieve 
them. Some designs will not yield the information required 
to realise the aims. The choice of design also depends 
on the availability of source populations and resources. 
Choosing an appropriate design requires balancing the 
pros and cons of various designs in view of study aims 
and practical constraints. We compare various cohort and 
case- control designs to estimate the effect of an exposure 
on disease incidence and mention how certain design 
features can reduce threats to study validity.
IntroduCtIon
Choosing an appropriate observational 
design to establish an association between an 
exposure or treatment and disease incidence 
is key to the success of the study. This paper 
describes design options and how to choose 
among them. Key points are summarised in 
figure 1.
observational studies to estimate an association 
between an exposure and disease incidence
In an observational study, the investigator 
does not control the exposure (or explan-
atory) variable of interest. Observational 
studies may be descriptive, such as studies to 
estimate secular trends in cancer incidence, 
but most assess possible causal associations. 
Here we focus on observational studies that 
estimate an association between an exposure and 
disease incidence in a particular population 
(the source population from which the study 
population was selected) over a specified 
time period (the risk period). Specifically, 
we consider cohort studies that include the 
entire source population or a sample from 
it and case- control studies that include the 
cases of disease and a sample of controls 
chosen from the same source population and 
risk period.
Establishing an association of an expo-
sure with disease incidence is often a first 
step on the quest to establish a causal effect. 
Experimental studies, in which the expo-
sure is controlled by the investigator (and 
may be allocated by randomisation), provide 
strong evidence for a causal association, but 
are not ethical for exposures like tobacco 
smoking, and also may be infeasible for 
practical reasons. In the absence of rando-
misation, exposures may be associated with 
other measured or unmeasured factors called 
confounders that can distort (or even hide) 
a true association between the exposure 
and health outcome or induce an apparent 
association when none exists. Therefore, no 
observational study can establish a causal rela-
tionship, but indicia, such as the strength of 
the association, dose response, and careful 
control for known confounding factors are 
helpful.1 2 Usually other lines of evidence, 
such as laboratory experiments to estab-
lish mechanisms, are required to buttress 
evidence of a causal relationship.
Because observational studies often 
provide the only information that can be 
gathered ethically, it is important to design 
them to be as convincing and informative as 
possible. A chief design objective is to achieve 
internal validity by having an adequate sample 
size, avoiding selection biases in recruiting 
the study sample, measuring the exposures 
and outcomes accurately, controlling for 
confounding, and performing appropriate 
analyses. In addition, one often desires 
that the results be generalisable to a target 
population (external validity). Although we 
mention some design choices pertinent to 
internal and external validity, readers are 
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Figure 1 Key points.
Figure 2 Designs for estimating an association between an 
exposure and disease incidence.
encouraged to consult excellent books and papers for 
details (eg,3–12).
The focus of this paper is on how to choose an appro-
priate observational study design from among several 
options, namely cohort studies; subsamples from cohorts, 
such as case- cohort and nested case- control designs; 
and population- based or hospital- based case- control 
studies. We discuss these designs later, but we introduce 
them here briefly (figure 2). In a cohort design, the 
cohort (study population) is obtained from the source 
population, baseline exposure and other covariates are 
measured, and cohort members are followed to deter-
mine disease incidence (figure 2A). In the case- cohort 
design,13 baseline exposure and covariate information 
are collected from all cases and from a random sample 
of the entire cohort (figure 2A). In the nested case- 
control design,14 baseline exposure and covariate infor-
mation are collected from cases arising among the cohort 
members and from controls time- matched to each case 
and selected from among non- cases at risk at the time 
the case develops (figure 2A). In a population- based 
case- control study, exposure and covariate information 
are collected from representative incident cases and 
from representative non- cases (controls) from the source 
population (figure 2B). In a hospital- based case- control 
study, exposures from incident cases of the disease of 
interest (disease A in figure 2C) are compared with expo-
sures from incident cases of another (control) disease (B) 
from the same hospital (figure 2C).
Estimating absolute risk, relative risk, absolute risk difference 
and relative odds of disease
To discuss these designs, we need to define measures of 
disease incidence and of exposure association with disease 
incidence for a cohort study. Incidence is a measure of the 
probability of the occurrence of a disease in a popula-
tion within a specific time period. Incidence may refer 
to the incidence proportion (also called absolute risk), which 
is the proportion of people in a population who develop 
disease during a specified period of time. Incidence may 
also refer to the incidence rate, which measures the occur-
rence of disease per unit of person- time.15 The relative 
risk is the ratio of two absolute risks, one for an exposed 
group and one for an unexposed group. The absolute risk 
difference is the corresponding difference in two absolute 
risks. The odds of disease corresponding to an absolute risk, 
AR, is AR/(1−AR). The relative odds (or OR) is the ratio 
of the odds of disease in an exposed group to the odds 
of disease in an unexposed group. These definitions are 
consistent with the terminology in BMJ Best Practice at 
https:// bestpractice. bmj. com/ info/ us/ toolkit/ learn- 
ebm/ how- to- calculate- risk/.
We illustrate computation of absolute risk, relative risk, 
absolute risk difference and relative odds (or OR) by an 
example. Table 1 describes hypothetical outcomes for 
a cohort consisting of 10 000 exposed and 20 000 unex-
posed individuals. After 10 years of follow- up, 100 cases of 
disease developed among exposed and 50 among unex-
posed individuals. The exposure- specific absolute risks 
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Table 1 Numbers of incident disease cases in a cohort 
study of 10 000 exposed and 20 000 unexposed individuals 
followed for 10 years
Exposed
Not 
exposed
Total 
population
Developed 
disease
100 50 150
Did not develop 
disease
9900 19 950 29 850
  10 000 20 000 30 000
of disease were therefore 100/10 000=0.01 and 50/20 
000=0.0025, respectively. The relative risk is the ratio of 
these absolute risks, 0.01/0.0025=4.0. The absolute risk 
difference is 0.01–0.0025=0.0075. The OR (or relative 
odds) is the ratio of the odds of disease in exposed individ-
uals, (100/9900), to the odds of disease in non- exposed 
individuals, (50/19 950). Here the OR is (100/9900)/
(50/19 950)=4.0303.
As illustrated in table 1, absolute risk is the probability 
of the disease of interest. ‘Risk’ is sometimes used synon-
ymously with absolute risk. Absolute risk is reduced by 
competing risks that kill an individual before the disease 
of interest develops.16 More generally, the competing 
risk can be any event that precludes subsequent observa-
tion of the event of interest. Some authors use the terms 
absolute risk or ‘pure’ risk for the risk of disease in the 
absence of competing mortality.16
Suppose that an investigator retrospectively measures 
the exposure status of the 150 individuals with disease 
(cases) in table 1 and of a random sample of 150 non- 
cases (or controls) from the 29 850 non- cases. The rela-
tive odds (or OR) of exposure in the case- control data is 
expected to be (100/50)/(9900/19 950)=4.0303, which 
equals the relative odds of disease in the cohort and is 
a good approximation to the relative risk, 4.0 for a rare 
disease.17 From these data on exposure alone, the case- 
control study cannot determine absolute risks, but if the 
disease risk in the source population is known (150/30 
000=0.005 in table 1), one can also estimate exposure- 
specific absolute risks (and risk differences) from case- 
control data.17–19
These ideas extend to studies of time to disease onset. 
The hazard rate (or incidence rate) is the instantaneous 
rate of disease at time t among survivors to t, and the relative 
hazard (or HR) is the ratio of two hazard rates. The inci-
dence rate is estimated by dividing the number of events 
that occur in a time interval by the corresponding cumu-
lative time at risk of cohort members (usually expressed 
in person- years). From cohort data, one can estimate inci-
dence rates as well as relative hazards.20 If one subsamples 
the cohort at baseline as in the case- cohort design,13 or 
uses a time- matched nested case- control study,14 one can 
estimate relative hazards and exposure- specific incidence 
rates, exposure- specific absolute risks over a specific time 
interval21 and relative risks. As mentioned previously, in 
the time- matched nested case- control design, controls are 
matched to each case by sampling from among non- cases 
at risk at the time the case develops. For further informa-
tion on estimation of relative hazards from nested case- 
control designs, see Greenland and Thomas,22 Pearce,23 
and Prentice and Breslow.24
A triumph of twentieth- century epidemiology was the 
demonstration of an increased risk of lung cancer in 
smokers. Among the most influential studies was a case- 
control comparison of smoking histories in patients with 
lung cancer with those in hospitalised patients with other 
diseases (controls).18 The strong relative odds found in 
that study was confirmed by the strong relative risks found 
in a later cohort study of British physicians.25 26
study aims, design choices and practicalities
The appropriateness of a study design depends on the 
research question. If the aim is to estimate exposure- 
specific absolute risk, then a case- control study alone, 
without information on overall risk in the source popula-
tion, will not provide the needed information.
Planned cohort studies are usually thought to be 
better than case- control studies because exposures and 
confounders can be reliably measured and recorded 
at baseline and are not subject to recall bias. However, 
cohort studies based on data collected routinely for 
other purposes, such as healthcare utilisation records, 
can suffer from measurement error and other threats to 
internal validity. Indeed, each of the designs in tables 2 
and 3 has strengths and weaknesses (sections 3 and 4). 
Whether a particular design yields valid results depends 
on feasibility and details of study design and execution.27
Practical considerations include cost, time required 
and access to relevant populations. Cohort studies of rare 
events require large samples and long follow- up. Cost 
or time constraints may preclude such a study. Lack of 
access to a relevant study population may be a factor. For 
example, a study of arsenic exposure in drinking water 
would be inefficient or futile if there was little variation of 
exposure in the available study population.
Thus choosing the best design among those that can 
address study aims involves a context- specific balance 
among competing considerations.9
dEfInIng thE rEsEArCh quEstIon
The most crucial aspect of study design is understanding 
and defining the primary research question and aims, 
and what is needed to achieve them. Some key issues are 
outlined here.
1. How will one measure the effect of the exposure on the health 
outcome? Ideally one can obtain exposure- specific abso-
lute risks, such as 0.01 for the exposed and 0.0025 for 
the unexposed in table 1. Exposure- specific absolute 
risks are needed to weigh the benefits and harms of 
an intervention, such as a programme to reduce ex-
posure or a new treatment, and some journals insist 
on including absolute risks whenever feasible. Often, 
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Table 2 Cohort study designs, including subsampling from the cohort
Data needed
Quantities that can 
be estimated Strengths Weaknesses
Prospective cohort 
study
Eligibility information; 
baseline exposure 
and other covariate 
information; dates of 
follow- up and diagnosis 
of disease(s)
Exposure- specific 
absolute risks; relative 
risks; absolute risk 
differences; other
Baseline exposure and 
other covariate data are 
less subject to ‘reverse 
causation’ or to recall bias. 
Ability to obtain updated 
exposure values; ability to 
estimate absolute risks of 
several health outcomes
Very large samples and long- 
term follow- up may be needed 
for rare outcomes. Not feasible 
to obtain extensive covariate 
information for all members of a 
large cohort.
Potential selection biases.
Potential differential follow- up by 
exposure group.
Case- cohort study; 
subcohort is a 
subsample of the 
prospective cohort
As for cohort except 
exposure and other 
covariate information 
only needed for cases 
and for the subsample
As for prospective 
cohort
As for cohort. Expensive 
laboratory tests and 
questionnaire processing 
only needed for cases and 
members of subcohort. 
Easy to estimate absolute 
risks of several health 
outcomes
Because one does not know 
at the outset who will develop 
disease, blood samples and 
unprocessed questionnaire data 
needed to be collected (but not 
analysed) for all members of the 
cohort. Mild loss of precision for 
estimating certain parameters, 
compared with full cohort.
Nested case- control 
study within a cohort; 
controls matched 
to cases on time (ie, 
age or time since 
recruitment) from 
those at risk at that 
time
As for cohort except 
exposure and other 
covariate information 
only needed for cases 
and for the matched 
controls
As for prospective 
cohort
As for cohort. Expensive 
laboratory tests and 
questionnaire processing 
only needed for cases and 
matched controls
As for case- cohort. Additionally, 
the controls are tailored to one 
disease.
Historical cohort 
study
Eligibility information; 
baseline exposure 
and other covariate 
information; dates of 
follow- up and diagnosis 
of disease(s). This is 
obtained from historical 
records
As for prospective 
cohort
Baseline exposure and 
other covariate information 
typically not subject 
to ‘reverse causation’. 
Because historical data are 
used, one does not need to 
wait for disease to develop.
Records (eg, industrial 
administrative files) may be 
incomplete, making it difficult 
to reconstruct who was in the 
cohort, to obtain accurate and 
complete follow- up information 
and to obtain accurate baseline 
exposure and other covariate 
information.
exposure- specific incidence rates (per person- year) 
that take follow- up time into account are required. 
The relative risk and relative hazard are estimable 
from cohort data and approximately from case- control 
data via the relative odds. Because a case- control study 
that collects new data can usually be conducted more 
quickly and cheaply than a new cohort study, estimates 
of relative odds and relative risks are widely used to 
identify risk factors for disease.
2. What is the nature of the exposure, and how will it be mea-
sured? The operational definition of the exposure 
needs to be clearly defined. If the exposure is the 
amount of exercise per week, this needs to be defined 
by protocols for a fitness- tracking device or items in 
a questionnaire, and if the exposure is a blood ana-
lyte, laboratory protocols for obtaining and measuring 
the analyte are needed. Procedures for quality control 
should be built into the design. To minimise artefacts 
from batch effects in laboratory measurements, cases 
and controls should be balanced within batches. If ex-
posures are measured repeatedly in the same individ-
uals over time, the measurement process and timing 
should be independent of disease status, if possible.
3. Which confounders need to be controlled for, and how? Con-
trol for confounding requires scientific understanding 
to identify risk factors for the outcome that are also 
possibly associated with exposure. Matched designs 
may enable better control for confounding (although 
it is still necessary to adjust for matching factors).7 28 
Analytical methods, such as multivariable regression 
or propensity scoring may be used to control for con-
founding, provided one is able to identify and measure 
potential confounders.
4. What is the target population for which results of this study 
might be informative? Relative risk estimates from one 
population may be similar to those found in other 
populations. Exposure- specific absolute risks are usu-
ally more heterogeneous. For example, estimates of 
the absolute risk of breast cancer from BRCA1 muta-
tions from women in families with many affected rel-
atives are higher than absolute risks in mutation car-
riers from the general population.29 Thus, one should 
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Table 3 Case- control designs that are not nested within an explicit cohort
Data needed
Quantities that can be 
estimated Strengths Weaknesses
Population- based 
incident case- 
control study
Eligibility information; 
representative samples 
of incident cases and 
controls from the 
source population. 
Retrospective 
information on 
exposure and other 
covariates, including 
possible laboratory 
measurements.
Relative odds of disease 
and relative risks of 
disease if controls 
are age- matched to 
cases. Only if external 
data on disease rates 
in the population are 
available can exposure- 
specific absolute risk be 
estimated.
Few controls needed, 
compared with cohort 
study. Time to accrue 
cases is short, compared 
with cohort study. 
Possible to obtain 
extensive information 
on exposure and other 
covariates.
Exposure and other covariates 
subject to recall bias and reverse 
causation. Low participation rates 
may lead to biased samples of 
cases or controls. Usually not 
possible to obtain serial exposure 
and other covariate measurements. 
Usually limited to a single health 
outcome. However, a single large 
control group may serve for several 
diseases in a study population.41
Hospital- based 
incident case- 
control study
Eligibility information; 
data from hospital cases 
and hospital controls 
with some other 
disease. Retrospective 
information on 
exposure and other 
covariates, including 
possible laboratory 
measurements.
Relative odds or relative 
risks with respect to the 
control disease(s), not 
necessarily with respect 
to the source population.
As for population- 
based incident case- 
control study. Higher 
participation rates than 
in general population 
and more willingness 
to provide biological 
samples.
As for incident case- control study. 
Also, the cases and controls may 
not be representative of the general 
population due to selection bias 
for a particular hospital. If the 
exposure is associated with the 
control disease, the exposure OR 
will be biased.
bear in mind the target population when choosing the 
source population and study sample.
5. Is this a hypothesis- driven study focused on a well- defined ex-
posure and outcome, or is it an exploratory study that exam-
ines many exposures or outcomes to discover an association? 
An example of hypothesis- driven research might be to 
measure the association of household radon exposure 
with lung cancer risk.30 The designs for hypothesis- 
driven research should focus on such issues as the sam-
ple size needed to detect a given exposure effect and 
can lead to compelling evidence about an association 
with disease. High throughput technologies that yield 
thousands of measurements on a single individual make 
exploratory (‘discovery’) studies attractive. For exam-
ple, comparisons of breast cancer cases and controls 
at hundreds of thousands of genetic loci (‘genome- 
wide association studies’) have led to the discovery of 
about 200 breast cancer- associated single nucleotide 
polymorphisms. Similarly, an exploratory cohort study 
of occupational formaldehyde exposure searched for 
mortality associations with 10 lymphohematopoietic 
malignancies.31 Exploratory studies require statistical 
procedures such as Bonferroni correction to reduce 
false- positive findings from multiple comparisons and 
need to be confirmed in independent data.32
6. Is the study large enough to provide sufficiently precise esti-
mates of the effect of the exposure? If confidence intervals 
on exposure effects are too broad, the study will not be 
convincing. Also, the proportion of false- positive ‘sta-
tistically significant’ findings is high in studies that are 
too small.33 Therefore, sample size calculations8 34 are 
needed to assure that the design meets objectives.
We focus next on hypothesis- driven studies with well- 
defined aims, such as: ‘The purpose of this study is 
to determine whether exposure X is associated with 
increased relative risk of disease D, compared with non- 
exposure to X, adjusted for confounders’.
Cohorts And subsAmplEs of Cohorts
Cohort designs
The prospective cohort design provides the most general 
type of information on disease incidence and is easy to 
understand (figure 2A, tables 1 and 2). Cohort members 
without the disease of interest are identified, exposures 
and covariates are recorded at date of entry into the 
cohort, and subsequent disease incidence is ascertained 
over the follow- up risk period. Related designs subsample 
a cohort (figure 2A and table 2). We consider dichoto-
mous disease outcome (yes or no) over a defined time 
period, as in table 1, but these ideas extend to studies of 
time to disease incidence. The time scale may be time 
since accrual into the cohort or age. In studies of disease 
incidence, age is often used because it is strongly asso-
ciated with disease incidence. In studies of death rates 
or disease recurrence rates following initial disease diag-
nosis, time since accrual (at initial diagnosis) is often 
used. The cohort study can estimate exposure- specific 
absolute risk, as well as relative risks of disease and any 
other function of the exposure- specific absolute risk.
The prospective cohort design has several advantages 
in addition to its ability to estimate exposure- specific 
absolute risks (table 2). First, covariates such as exposure 
X and potential confounders are measured at baseline, 
before they are influenced by the effects of incident 
disease. Avoidance of such ‘reverse causation bias’ (for 
example, diet changes in response to incident disease) 
and the ability to obtain high- quality exposure data at 
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baseline are reasons for choosing this design for expo-
sures like diet. Second, cohort studies can be designed 
to provide serial measurements on exposure (and other 
covariates) to study associations of exposure trends with 
disease incidence. Such cohort studies are often called 
longitudinal studies. Third, cohorts can provide data on 
the disease of primary interest and on other diseases. 
Thus, a single study might provide estimates of the associ-
ation of X with several diseases. Fourth, although models 
such as the Cox proportional hazards model20 are often 
used to analyse time- to- event cohort data, many model-
ling approaches, such as Aalen's additive hazard model,35 
can be estimated with cohort data.
The chief disadvantage of the cohort design concerns 
sample size and study duration for a moderately rare 
outcome, such as cancer incidence or stroke incidence 
(table 2). The cohort needs to be large and the follow- up 
long to observe the number of incident cases required 
for sufficiently precise estimation of absolute risk or rela-
tive risk. If the exposure is also rare, such as a drug expo-
sure or genetic mutation, even larger sample sizes are 
needed. The large required sample size limits the ability 
to capture detailed covariate information. For example, 
among 306 473 men and women, aged 40–73 years and 
followed for a median of 7.1 years in the UK Biobank 
Study, 287 suffered intracerebral haemorrhagic strokes,36 
which is adequate to detect some associations, but not 
modest associations or associations with rare exposures. 
Because the statistical information in a cohort study of a 
rare event increases with the number of events observed, 
there can be a trade- off between study duration and the 
number of participants enrolled. Ten thousand partic-
ipants followed for 20 years provide as much informa-
tion on relative risk as 50 000 participants followed for 4 
years. The longer study, however, yields data on long- term 
effects of exposure on absolute and relative risk. Cohort 
studies of events with high absolute risk, such as cancer 
recurrence following treatment of lung cancer, do not 
need to be very large or long.
Other potential limitations of cohort studies should 
be mentioned. It may not be feasible to collect extensive 
information on potential confounders in a large cohort. 
Because covariate information may be limited, inade-
quate control for confounding may yield biased estimates 
of relative risk. If the follow- up procedures for disease 
ascertainment differ between exposed and unexposed 
cohort members, biased estimates of relative risk may 
result. The available study cohort may not be represen-
tative of the general population, limiting the generalis-
ability of the result.
It took 10 years to accumulate the cases in table 1. 
One way to shorten such a study is to look for a ‘histor-
ical cohort’ that was previously established (table 2). For 
example, a mining company may have records to iden-
tify previous employees. If it were possible to retrieve 
information on the employees’ exposures and on their 
previously incident health outcomes, one could analyse 
the cohort data without waiting for incident cases to arise. 
The historical cohort design may provide imperfect infor-
mation, however. Data on exposure and disease ascertain-
ment may be incomplete. Records of who was employed 
may be incomplete. Unrecorded employees who stay well 
may remain unidentified, whereas unrecorded employees 
who develop disease may make health claims and be 
recorded as having events, which can bias incidence rates 
upwards. Electronic health records in national databases 
or health maintenance organisations yield historical 
cohort data with information on exposures like medica-
tion use and on health outcomes but may provide limited 
data on confounders.
nested case-control design
Sometimes an exposure such as a blood analyte may be 
too costly to measure on all members of a cohort. Blood 
samples may have been obtained and stored on all cohort 
members, but it may be much less expensive to perform 
the assay only on individuals who develop disease and 
appropriately selected controls (figure 2A and table 2). 
For each case, the nested case- control design14 selects r 
controls without replacement from among all cohort 
members who remain free of the disease at the time of 
incidence of the case. Exposure information is needed on 
(r+1) times the number of incident cases. Thus, in table 1, 
with N=30 000 people, 150 incident cases and r=2 controls 
per case, exposure data would be needed on 3×150=450 
individuals. The nested case- control design gives valid 
estimates of relative hazards for studies of time to disease 
onset.14 24 It rarely pays to choose more than r=4 controls 
for each case, because the limiting factor for precise 
estimation of the relative hazard becomes the number 
of cases, not controls.37 For precise estimation of very 
large or small relative hazards, however, more controls 
are useful.38 The nested case- control design yields valid 
estimates of the relative hazard, and the exposure- specific 
absolute risk of disease may be estimated by reweighting 
the control sample to the cohort population.21 39 40
Nested case- control studies are subject to the potential 
weaknesses mentioned for the full cohort except that it 
is feasible to analyse more baseline data to control for 
confounding in the nested case- control study. Nested 
case- control studies can also investigate associations with 
newly discovered analytes. These advantages can only 
be realised if the raw questionnaire data and biological 
samples were stored for the full cohort at baseline, and 
if the initial informed consent or a reconsent process 
allowed for later investigations.
Case-cohort design
A potential disadvantage of the nested case- control 
design is that controls are time- matched to cases of a 
particular disease. If one wishes to study exposure associa-
tions with another type of disease, new controls will need 
to be chosen. The case- cohort design13 41 avoids this diffi-
culty by selecting a random subcohort from the cohort 
and comparing the baseline exposures of incident cases 
that arise in the cohort with baseline exposures in the 
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subcohort (figure 2A and table 2). For example, a subco-
hort of 500 (1.67% random sample of original cohort of 
30 000) might be used for comparisons against the 150 
incident cases that arose in table 1, (of whom about 1.67% 
× 150=3 are subcohort members). As for the nested case- 
control design, the success of this strategy depends on 
having stored blood samples (or other materials or data 
needed for exposure assessment) on all cohort members, 
but only performing the exposure assessment on incident 
cases and subcohort members. In the previous example, 
exposure assessments would be required on approxi-
mately 150 + (500–1.67% × 150)=647 individuals, instead 
of 30 000. A great advantage of the case- cohort design is 
that the same subcohort can be used to study associations 
with several different diseases. This design also yields 
simple estimates of exposure- specific absolute risk as well 
as relative risks (table 2).
As for the nested case- control design, baseline ques-
tionnaire data and biological samples are needed for all 
cohort members, even if they will only be analysed for 
incident cases and the subcohort, and special studies on 
newly discovered analytes need to be authorised by the 
initial informed consent or by a reconsent procedure.
CAsE-Control dEsIgns not nEstEd In A Cohort
population-based case-control design
Although the nested case- control design is efficient 
for sampling from a well- defined cohort, often it is not 
possible to enumerate a suitable cohort. Nonetheless, 
it may be possible to obtain a random sample, or even 
an exhaustive sample, of all the incident cases that 
arise in a given region in a fixed time period as well as 
a random sample of non- cases from this source popula-
tion (figure 2B and table 3). To avoid bias, it is important 
that the cases be representative of all incident cases and 
the controls be representative of all non- cases.17 22 These 
population- based cases and controls constitute the study 
population.
The population- based case- control design is usually less 
expensive and time- consuming than a new cohort study 
with primary data collection. The incident cases can be 
ascertained in a comparatively short time because they 
derive from a large source population. It is rarely neces-
sary to sample more than r=4 controls per case.37 42
The population- based case- control design has addi-
tional advantages. Because one can focus on a smaller 
number of individuals, one can obtain detailed informa-
tion on possible exposures and confounders. Also, if one 
knows the disease incidence rate in the source population, 
one can estimate relative risks (cumulative ORs, incident 
rate ratios/relative hazards, or relative risks, depending 
on how the controls were sampled and rarity of disease22) 
and exposure- specific absolute risk.17
The population- based case- control design also has 
weaknesses (table 3). First, absolute risk cannot be esti-
mated unless external information on disease incidence 
in the source population is available. Second, not all the 
randomly selected cases and controls will agree to partic-
ipate in the study, particularly if biological specimens are 
required. Thus, the participating cases and controls may 
not be representative, and if, for example, exposed cases 
tend to participate more than exposed non- cases, biased 
ORs will result. Third, participants' recall of informa-
tion on previous exposure and other covariates may be 
faulty. A particularly harmful form of misinformation on 
exposure is ‘differential recall bias’, whereby cases have 
a different perception of previous exposures than non- 
cases, resulting in biased ORs. Studies of dietary expo-
sures are subject to such bias, for example. Even if the 
exposure is based on a laboratory measurement, a form 
of differential measurement error (‘reverse causation’) 
may result because the preclinical disease process may 
affect an individual's biochemistry or appetite, even 
though the biochemical feature did not cause the disease. 
In such circumstances, it is best to use a cohort design or 
a nested case- control design or case- cohort design with 
previously stored biological specimens or questionnaire 
data. Studies of medical treatments and drug exposures 
are especially subject to bias from reverse causation 
(sometimes called ‘confounding by indication’), because 
the disease or its precursors may dictate the treatment, 
rather than the treatment affect the disease. This can be 
problematic even in cohort studies. Not all exposures are 
subject to biased retrospective assessment, however. For 
example, genotypes measured in case- control studies are 
not subject to recall bias or reverse causation.
Sometimes a case- control study includes prevalent 
as well as incident cases. A prevalent case is a person 
whose disease developed before the study began and 
who survived to the beginning of the study. If the expo-
sure of interest for disease incidence also affects survival 
following disease incidence, estimates of relative risks for 
incidence can be distorted by inclusion of the prevalent 
cases. Because the relative risk of disease incidence is a 
key parameter for studying disease aetiology, prevalent 
cases should be excluded or used with caution in such 
studies.43
hospital-based case-control design
It may not be feasible to obtain representative population- 
based random samples of cases and controls if randomly 
selected individuals refuse to provide blood samples, for 
example. An alternative is to recruit cases at a hospital 
and to select as controls patients at the same hospital 
with diseases thought to be unrelated to the exposure 
(figure 2C and table 3). Cases and controls recruited in 
the hospital setting are likely to consent to have blood 
drawn for study. If the cases (disease A in figure 2C) 
are representative of cases in the source population 
with respect to exposure and if control cases (disease B 
in figure 2c) are also representative of non- cases in the 
source population with respect to exposure, then expo-
sure ORs comparing cases to controls will be similar 
to those from a population- based study. However, two 
features of hospital- based case- control designs render 
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them especially susceptible to bias, in addition to imper-
fect recall that affects all case- control designs. First, 
disease A cases that come to a given hospital and patients 
with disease B that come to that hospital (and serve as 
controls) may not be representative of disease A cases or 
disease B cases in the source population, because factors 
such as socioeconomic status may influence who goes to 
a particular hospital (dotted lines in figure 2C). Using 
disease B controls from the same hospital will not cause 
such selection biases if the selection forces act equally on 
patients with diseases A and B. However, this is not always 
true and is hard to verify. For example, the hospital may 
specialise in disease A, meaning that its catchment area 
is wide, whereas patients with the control disease B may 
come from near the hospital. The two groups may differ 
in social status, which may induce bias. The second major 
assumption is that the control disease B is not associated 
with the exposure. If the exposure is positively associated 
both with disease A and with disease B, the exposure ORs 
will be biased towards unity. For example, one of the first 
case- control studies of the association of lung cancer with 
smoking used patients with cardiovascular disease and 
with respiratory disease among the controls.18 In view 
of the known association of smoking with these control 
diseases, as is now understood, it is likely that the ORs 
with smoking found by Doll and Hill,18 though very large, 
were attenuated compared with what would have been 
observed with population- based controls.
Another weakness of hospital- based case- control 
studies is that they do not yield estimates of absolute risk 
(table 3).
dIsCussIon
We emphasised the importance of defining the study aims 
as the key step in study design. Choosing an appropriate 
design requires balancing resources and study elements 
to best meet the study aims. For studying associations of 
an exposure with disease incidence, we catalogued the 
major design options and their strengths and weaknesses 
(see also Borgan et al44).
We mentioned some features of these designs that 
can threaten or enhance internal validity. The reader is 
encouraged to consult texts such as Breslow and Day, and 
Rothman et al7–9 for details. We now review these themes. 
Exploratory studies have special threats to internal validity 
because apparent associations will arise by chance if many 
exposures or many disease subtypes are examined. Some 
threats to internal validity can be mitigated by careful 
design. Analysis of covariate information can help control 
for confounding, and matched designs may facilitate and 
improve such analyses. Both approaches require identi-
fying and measuring the potential confounders before-
hand. Measurement error in exposure, confounders or 
outcome ascertainment threatens internal validity, and 
the study design and planning should try to reduce such 
errors by perfecting questionnaires, measurement instru-
ments and follow- up procedures. If a laboratory assay has 
substantial batch- to- batch variability, then including cases 
and controls in each batch can reduce potential biases. 
Efforts to improve participation rates by those invited 
for a study can reduce selection biases. Missing data pose 
a threat to internal validity, especially if missingness is 
related to exposure or outcome, which will be difficult 
or impossible to know. Special procedures to obtain 
complete data on exposure and key covariates may be 
helpful. The design should specify the proposed analysis 
and required sample size to meet study objectives. Pilot 
studies to test the feasibility of the design and measure-
ments are highly desirable and usually indispensable.
Even if the study is internally valid, the generalisability 
of the result to a target population may be questionable 
if the source population for the study differs from the 
target population. Thus, the target population needs to 
be considered when planning the study.
We have mentioned many factors to be considered 
in designing a study to estimate an association between 
an exposure and disease incidence. But none is more 
important than careful delineation of study aims and 
assuring that the chosen design, as outlined in figure 2 
and tables 2 and 3, can meet those aims.
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